Company Participants
Gayathri Diwakar – Senior Director of Investor Relations
R. Struthers – Founder, President, CEO & Director
Isabel Kalofonos – Chief Commercial Officer
Alan Krasner – Chief Endocrinologist
Tobin Schilke – Chief Financial Officer
Conference Call Participants
Joseph Schwartz – Leerink Partners LLC, Research Division
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Research Division
Maxwell Skor – Morgan Stanley, Research Division
Jonathan Wolleben – Citizens JMP Securities, LLC, Research Division
Jessica Fye – JPMorgan Chase & Co, Research Division
Yuchen Ding – Jefferies LLC, Research Division
Katherine Kaiser-Dellorusso – LifeSci Capital, LLC, Research Division
Alexander Thompson – Stifel, Nicolaus & Company, Incorporated, Research Division
Nicholas Lorusso – TD Cowen, Research Division
Douglas Tsao – H.C. Wainwright & Co, LLC, Research Division
Jin Law – Goldman Sachs Group, Inc., Research Division
Catherine Novack – JonesTrading Institutional Services, LLC, Research Division
Brian Skorney – Robert W. Baird & Co. Incorporated, Research Division
Presentation
Operator
Hello, everyone. Thank you for joining us, and welcome to the Crinetics Pharmaceuticals First Quarter 2026 Financial Results. [Operator Instructions] I will now hand the conference over to Gayathri Diwakar, Head of Investor Relations. Gayathri, please go ahead.
Gayathri Diwakar
Senior Director of Investor Relations
Thank you, operator. Good afternoon, everyone, and thank you for joining us to discuss the first quarter 2026 results. Today on the call, we have Dr. Scott Struthers, Founder and Chief Executive Officer; Isabel Kalofonos, Chief Commercial Officer; Dr. Alan Krasner, Chief Endocrinologist; and Tobin Schilke, Chief Financial Officer.
Please note, there is a slide deck for today’s presentation, which is in the Events and Presentations section of the Investors page on the Crinetics website. In addition, a press release was issued earlier today and is also available on the corporate website.
Slide 2. As a reminder, we’ll be making forward-looking statements, and I invite
